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Glioblastoma is most common type of brain tumour with an extremely poor prognosis due to 
lack of effective treatment options. CIZ1, a protein found to be implicated in a range of cancers, 
has been identified as a potential biomarker. CIZ1 has a role in the replication of DNA and cell 
cycle control through the coordination of cyclin A and E within the nucleus. This study will 
evaluate the use of CIZ1 as a biomarker in advanced glioblastoma. Immunohistochemistry 
showed that CIZ1 expression is increased in 6/6 FFPE tissue sections. In FFPE patient 
samples CIZ1 is expressed primarily in the cytoplasm, and that its expression can be used to 
distinguish between normal and tumour cells. In addition, using primary glioblastoma cells 
(BTNW914) depletion of CIZ1 reduced proliferation, suggesting that CIZ1 may promote 
tumour growth. Furthermore, preliminary evidence demonstrates that CIZ1 levels can be 
reduced by inhibition of CDK and DDK inhibitors that reduce CIZ1 levels in vitro. These results 
suggest that CIZ1 could be a potential useful diagnostic and prognostic biomarker and a target 
for therapeutic intervention.  
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Chapter 1: Introduction 
  





Gliomas are the most common type of brain cancer, which are believed to arise from the 
neuroepithelial group of cells, which include neural stem cells (NSCs), astrocytes or 
oligodendrocyte precursor cells, although there is some debate regarding this in literature. The 
World Health Organisation (WHO) classifies astrocytic gliomas based on histologic criteria 
from low-grade lesions (grades I–II) to high-grade (grades III–IV) malignancies. Glioblastoma 
is classified as grade IV. Glioblastoma is the most common and most aggressive malignant 
brain tumour with a 5.1% 5-year survival rate (Ostrom et al., 2015) and a ~10 month median 
survival (Zhu et al., 2017). There are currently no effective treatments, therefore there is an 
unmet clinical need to identify new therapeutic targets and develop more effective treatments. 
 
Cip1-interacting zinc-finger protein 1 (CIZ1) is a protein found to implicated in a range of 
cancers, with a role in promoting tumour growth. Here we aim to identify whether CIZ1 is 
expressed in glioblastoma, to determine if its expression is altered in glioblastoma, and to 
establish if reduction in CIZ1 levels reduces primary glioblastoma cell line proliferation. The 
literature review here will provide an overview of glioblastoma, its clinical manifestation and 
molecular biomarkers. In addition, an overview of CIZ1 function in normal cell proliferation and 




Glioblastoma is the most common type of brain tumour, with an incidence rate of 3.19 in 
100,000 (Thakkar et al., 2014) and a global incidence rate of approximately 10 in 100,000 
(Iacob and Dinca, 2009). Additionally, there is evidence that incidence is increasing further, 
with studies showing a similar percentage rise across different age groups, despite the large 




differences in number of cases for each group, which suggests a widespread environmental 
factor may be responsible (Dobes et al., 2011, Philips et al., 2018).  
 
Glioblastoma accounts for 50% of all gliomas in all age groups (Rock et al., 2012). It can occur 
at any age, but the peak incidence occurs between 75 to 79 years (Thakkar et al., 2014, Li et 
al., 2018). The ratio of glioblastoma incidence is higher in men compared to women, with a 
3:2 M:F ratio (Ohgaki and Kleihues, 2005, Thakkar et al., 2014). Caucasians are affected more 
frequently than other ethnicities: Europe and North America 3-4 per 100,000 whereas Asia 
0.59 per 100,000 (Louis et al., 2016). Glioblastoma patients have a poor prognosis with a 1-
year post-diagnosis survival rate of 37.2%, a 2 year survival rate of 13.7%, and a 5-year 
survival rate of 5.1% (Ostrom et al., 2015, Thakkar et al., 2014). Median survival post-
diagnosis is approximately 10 months (Zhu et al., 2017).  
 
1.2.2 Genetic and Molecular pathogenesis  
Traditionally, glioblastomas have been divided into primary and secondary tumours. In the 
current (2016) World Health Organisation (WHO) classification of CNS tumours, 
glioblastomas are characterised into two main groups: Isocitrate dehydrogenase (IDH) wild-
type which correlates closes with primary glioblastoma, and IDH mutant, which correlates 
closes with secondary glioblastoma (Louis et al., 2016). A third classification exists whereby 
IDH status is unavailable or indeterminate, therefore is classified as glioblastomas NOS (not 
otherwise specified) (Table 1.1). 
 
Primary glioblastomas are those that arise de novo, accounting for 90% of all glioblastomas. 
Primary glioblastomas are the more aggressive type and they tend to occur in elderly patients, 
with a mean age of 62 years. They often have amplification of Epidermal Growth Factor 
Receptor (EGFR), overexpression of Mouse Double Minute 2 Homolog (MDM2) and mutation 
in  Phosphatase And Tensin Homolog (PTEN) (Ohgaki and Kleihues, 2013). Three 




glioblastoma histological variants are recognised: giant cell glioblastoma, gliosarcoma and 
epithelioid glioblastoma (Louis et al., 2016).  
 
Secondary glioblastomas, in contrast, are those which arise from a pre-existing lower grade 
diffuse astrocytoma or anaplastic astrocytoma, generally identifiable by their IDH mutant 
status. They are relatively uncommon, only accounting for approximately 10% of all 
glioblastomas. These tumours tend to be less aggressive than primary glioblastomas and they 
tend to occur in younger patients (Louis et al., 2016, Ohgaki and Kleihues, 2013). Secondary 
glioblastomas also demonstrate p53 mutations, amplification of Platelet-Derived Growth 
Factor Subunit A (PDGF-A), loss of heterozygosity of chromosomes 10q and 17p, loss of 19q 
and increased telomerase activity and Human Telomerase Reverse Transcriptase (hTERT) 
expression (Ohgaki and Kleihues, 2013). They are almost always O6-methylguanine-DNA 
methyltransferase (MGMT) methylated (Mulholland et al., 2012). 
 
WHO classification Markers 




Secondary glioblastoma IDH mutation 
p53 mutation 
PDGF-A amplification 
Loss of heterozygosity of chromosomes 10q 
and 17p 
19q deletion 
Increased telomerase activity  
Increased hTERT expression 
MGMT methylation. 
NOS No distinct markers 
Table 1.1: WHO classification of glioblastoma tumours. Subdivision of glioblastomas  
based on the molecular changes (Louis et al., 2016). 
 
Based on gene expression profiling of patient tumours, The Cancer Genome Atlas (TCGA) 
analysis classifies glioblastoma into four subgroups: classical, mesenchymal, proneural and 




neural. Each of these subtypes has its own distinct signature (Verhaak et al., 2010, Cancer 
Genome Atlas Research, 2008) (Table 1.2). The classical subtype is categorised by the loss 
of cyclin dependent kinase inhibitor 2A (CDKN2A) and EGFR amplification, in addition to 
chromosome 7 amplification and chromosome 10 deletion. The hallmarks of proneural 
transcriptional subclass are Platelet Derived Growth Factor Receptor Alpha (PDGFRA), TP53 
and the most frequent IDH1 mutations. Mutations neurofibromin 1 (NF1) and PTEN are  the 
main features of mesenchymal subtype. The neural subtype currently has no unique genetic 
signature (Cloughesy et al., 2014, Verhaak et al., 2010).  
TCGA classification Markers 
Classical CDKNA2 deletion 
EGFR amplification/mutation 
Chromosome 7 amplification 
Chromosome 10 deletion 
Mesenchymal NF1 mutation 
PTEN mutation 
Proneural IDH1 mutation 
PDGFRA mutation 
TP53 mutation 
Neural No distinct markers 
Table 1.2: The Cancer Genome Atlas classification of glioblastoma tumours. Subdivision 
of glioblastomas  based on the molecular changes (Verhaak et al., 2010). 
 
1.2.3 Diagnosis and Early Detection 
The current methods used for diagnosis are conducting brain scans, such as magnetic 
resonance imaging (MRI) or a computed tomography (CT) scan (Shukla et al., 2017, Miletich, 
2016). Subsequently, a biopsy will then be taken to allow a more accurate diagnosis of the 
tumour type. Clinical presentation of symptoms such focal neurological deficit and cognitive 
impairment as a direct effect necrotic destruction of brain tissue, headaches due to increased 
intercranial pressure caused by tumour growth and increased oedema, and seizures 
depending on size and location of the tumour (Alexander and Cloughesy, 2017, Duhrsen et 
al., 2019). One of the main issues with current diagnosis techniques is that the tumour is 
identified already at a late stage, which contributes to poor prognosis.  





Typical histological features of glioblastoma include regions of necrosis, microvascular 
proliferation, abundant mitoses, and pleiomorphic cells (Urbanska et al., 2014, Wen and 
Kesari, 2008). These features are used to assist in grading and diagnosis. According to The 
National Institute For Health And Care Excellence (NICE) guidelines following the latest 
version of the WHO classification for gliomas, the recommended molecular markers for 
diagnostic use include: IDH1 and IDH2 mutations, ATRX chromatin remodeler (ATRX) 
mutations to identify IDH mutant astrocytomas and glioblastomas, 1p/19q codeletion to 
identify oligodendrogliomas, histone H3.3 K27M mutations in midline gliomas and B-Raf proto-
oncogene, serine/threonine kinase (BRAF) fusion and gene mutation to identify pilocytic 
astrocytoma (Louis et al., 2016). Other molecular markers suggested for determining 
prognosis and guide treatment include MGMT promoter methylation (Hegi et al., 2005, 
Mulholland et al., 2012) and TERT promoter mutations (Lee et al., 2017) in IDH-wildtype 
gliomas (Louis et al., 2016). EGFR amplification/mutation is a common feature of classical 
subtype (An et al., 2018, Gan et al., 2009, Struve et al., 2020). There is also work looking into 
the use of microRNAs as potential circulating biomarkers, which would prove extremely useful 
in terms of diagnosis, as being able to test without the need for a biopsy would reduce costs 
and time, whilst  increasing safety for the patient (Tumilson et al., 2014, Hayes et al., 2015, 
Saadatpour et al., 2016). 
 
1.2.4 Current and potential future treatments 
There is currently no effective cure for glioblastoma, with the last breakthrough being the 
introduction of temozolomide initially as a second line therapy, then as a result of larger trials 
was approved as a front-line drug in 2007 (NICE, 2001). The current standard of treatment is 
surgical resection to the extent feasible, followed by adjuvant radiotherapy or chemotherapy 
(Stupp et al., 2005). It has been shown that temozolomide in addition to radiation for a 
subgroup of patients with a methylated MGMT promoter results in a modest but significant 




improvement in survival (Hegi et al., 2005, Stupp et al., 2005). Despite the significant 
improvements seen using the Stupp protocol, resulting in 26.5% 2 year survival from a 10.4% 
survival seen with radiotherapy alone, glioblastoma tumours are resistant to these 
conventional therapies, rendering them still mostly ineffective, with a median  survival rate of 
15-16 months (Bi and Beroukhim, 2014). 
 
Tumour Treating Fields (TTFs) is a research area that is gaining traction since their discovery 
in 2004 (Hottinger et al., 2016, Kirson et al., 2004), gaining approval for use in treatment of 
recurrent glioblastoma in 2011, then approved to treat newly diagnosed glioblastoma in 2015. 
This novel therapy applies low intensity, intermediate frequency, alternating electrical fields to 
damage rapidly dividing tumour cells by disrupting of cytokinesis, and interfere and prolong 
cell division, resulting in apoptosis (Rick et al., 2018, Burri et al., 2018). The EF-14 clinical trial 
was conducted to evaluate the efficacy and safety of TTFs used in combination with 
temozolomide maintenance treatment after chemoradiation therapy for patients 
with glioblastoma (Stupp et al., 2015). To investigate whether TTFs improves progression-free 
and overall survival of patients with glioblastoma, the EF-14 clinical trial demonstrated that 
adding TTFs to standard therapy improved OS (5-year OS: 13% vs 5%, P = .004) with no 
negative impact on quality of life. (Stupp et al., 2017, Stupp et al., 2015). Despite approval of 
use, incorporation of TTFs into glioblastoma treatment has been somewhat slow, due to 
concerns about its cost, practicality of its usage from a patient perspective, and some 
slowness of the medical and scientific community to embrace its unconventional mechanism 
(Rick et al., 2018). 
 
There are currently numerous ongoing clinical trials for adult glioblastoma, many of which are 
testing adjuvants to current treatment. Others are involved with treating symptoms, 
differentiating patients in response to treatment and improving diagnostic techniques. There 
are two ongoing studies called PARADIGM and PARADIGM-2 which are running in parallel 




using Poly(ADP-ribose)polymerase (PARP) inhibitor olaparib alongside radiotherapy or 
radiotherapy and chemotherapy respectively (Fulton et al., 2018). PARP is an essential 
enzyme in base excision repair and single strand break DNA repair, which includes DNA 
lesions which arise from radiation treatment (del Rivero and Kohn, 2017). The safety and 
tolerability of olaparib with radiotherapy was confirmed by phase 1 of the PARADIGM clinical 
trial (Chalmers et al., 2017) in addition to three parallel phase I studies looking at different 
cancers (de Haan et al., 2019). Another ongoing trial currently recruiting is the Ipi-Glio trial, a 
phase II randomised study of ipilimumab with temozolomide versus temozolomide alone after 
surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma (Brown et 
al., 2020). Ipilimumab is a monoclonal antibody which targets cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), a protein receptor that downregulates the immune system 
(Alaia et al., 2018). Cytotoxic T lymphocytes (CTLs) can recognise and destroy cancer cells. 
Ipilimumab is already clinically approved for treating melanoma (Specenier, 2016), with clinical 
trials for prostate (Beer et al., 2017, Beer et al., 2012), small cell lung cancer (Antonia et al., 
2016), non-small cell lung cancer (Hellmann et al., 2017) and bladder cancer (Galsky et al., 
2018). 
 
There are other potential avenues for glioblastoma treatment. EGFR amplification is common 
in the classical subtypes of glioblastoma. Several randomised phase III studies have revealed 
that treatment with EGFR tyrosine kinase inhibitors results in an improved progression-free 
survival compared to standard chemotherapy in chemonaive patients with advanced non-
small cell lung cancer, selected based on the presence of EGFR mutations (Takeda and 
Nakagawa, 2019).  There was a phase I/II clinical trial that had been approved which was 
proposing to use EGFR bispecific antibody (EGFRBi)-armed autologous T cells in treating 
patients with recurrent or refractory glioblastoma, which was withdrawn due to lack of funding 
and a primary co-investigator of the trial leaving the institution (Zitron et al., 2013).  
 





1.3.1 CIZ1 Discovery 
Cip1-interacting zinc-finger protein 1 (CIZ1) is a protein discovered as a novel binding partner 
of p21Cip1/Waf1 in a yeast two-hybrid screen which used Cyclin E/p21Cip1/Waf1 as bait (Mitsui et 
al., 1999). A region of about 150 amino acids containing the first zinc-finger motif in CIZ1 was 
shown to be the binding site for p21Cip1/Waf1. 
 
CIZ1 is comprised of 842 amino acid residues, containing two glutamine-rich domains, three 
C2H2-type zinc finger motifs, an acidic domain, and a matrin 3 type zinc finger (MH3) domain 
(Mitsui et al., 1999). The C-terminal domain containing the three zinc-finger motifs and MH3 
anchors CIZ1 to the nuclear matrix (Ainscough et al., 2007), where the N terminal, which 
contains polyglutamine repeats and glutamine-rich region, promotes DNA replication initiation 
but cannot bind the nuclear matrix (Coverley et al., 2005, Copeland et al., 2010). CIZ1 is 
associated with the nuclear matrix (Ainscough et al., 2007) and is non-essential in mice, with 
CIZ1 null mice showing no severe developmental defects (Nishibe et al., 2013). 
 
1.3.2 CIZ1 function in initiation of DNA replication and cell cycle regulation 
DNA replication is a spatially and temporally controlled to ensure that DNA replication happens 
once per cell cycle. This requires the formation of specific complexes: the pre-replication 
complex (pre-RC), pre-initiation complex (pre-IC)/helicase activation and replisome formation 
that enable reproducible and high-fidelity duplication of the genome. The process of pre-RC 
assembly begins with the origin recognition complex (ORC) binding to DNA at AT rich motifs, 
serving as a platform for replication machinery to bind. MCM2-7 complex loading is mediated 
by sequential rounds of binding and release of Cdc6 and Cdt1 (Edwards et al., 2002, Yardimci 
and Walter, 2014). Each round loads a single MCM2-7 complex, resulting in two MCM2-7 
complexes loaded in opposing orientations that ‘licenses’ origins for DNA replication. 




Formation of the Pre-IC is driven by cyclin E/CDK2 and DDK activity, which promotes 
recruitment of CDC45-MCM2-7-GINS (CMG) complex. MCM10 aids in activation of CMG via 
recruitment of Cdc45 and stimulating DDK phosphorylation of MCM2, which thereby leads to 
GINS attachment to MCM2–7 (Perez-Arnaiz et al., 2016). Also, MCM10 can aid activation 
through direct binding with MCM2-7 complex (Douglas and Diffley, 2016) This allows helicase 





















Figure 1.1: Initiation of DNA replication. The origin recognition complex (ORC) binds to 
DNA. MCM2-7 complex loading is mediated by sequential rounds of binding and release of 
Cdc6 and Cdt1 (Edwards et al., 2002, Yardimci and Walter, 2014). Each round loads a single 
Mcm2-7 complex, resulting in two Mcm2-7 complexes loaded in opposing orientations that 
‘licenses’ origins for DNA replication. Formation of the Pre-IC is driven by cyclin E/CDK2 and 
DDK activity, which promotes recruitment of CDC45-MCM2-7-GINS (CMG) complex. MCM10 
aids in activation of CMG via recruitment of Cdc45 and stimulating DDK phosphorylation of 
MCM2, which thereby leads to GINS attachment to MCM2–7 (Perez-Arnaiz et al., 2016). 
MCM10 aids activation through direct binding with MCM2-7 complex (Douglas and Diffley, 
2016) allowing helicase activity to commence and DNA replication to begin. CIZ1 is a nuclear 
matrix protein binding to Cdc6 and facilitating cyclin E – CDK2 then cyclin A – CDK2 
recruitment to replication complex (Copeland et al., 2015, Copeland et al., 2010, Coverley et 
al., 2005). Figured adapted from (Pauzaite, 2019) 
 
 
The process of DNA replication is tightly regulated by CDK activity. Oscillating CDK activity 
seen throughout the cell cycle is important for restricting DNA replication occurs only once per 
cell cycle, ensuring genomic integrity is maintained, and contributes to separation of replication 




licensing from replication origin firing (Figure 1.2). Pre-RC assembly begins in later mitosis in 
cycling cells, as CDK activity drops due to APC/C activation, cyclin degradation and 
phosphatase activation (Zhang et al., 2016, Fragkos et al., 2015).  These events are restricted 
to early G1 phase while CDK activity remains low. Pre-RC assembly is inhibited during mid to 
late G1 phase when CDK activity rises leading to phosphorylation of pre-RC components 
Orc2/6, Cdc6 and Cdt1, resulting in cytosolic localisation or proteasomal degradation (Chen 
and Bell, 2011, Walter et al., 2016, Johansson et al., 2014, Drury et al., 2000, Mimura et al., 
2004, Diril et al., 2012). If CDK activity is too high, CDK mediated phosphorylation of DNA pol 
α prevents initiation of  DNA replication (Voitenleitner et al., 1997, Voitenleitner et al., 1999). 
 
 
Figure 1.2: Cyclin-CDK control of the cell cycle. Cyclin D is expressed and activates 
CDK4/6 in early G1 phase (blue). Cyclin E is expressed and activates CDK2  in mid- G1 
(orange), raising total kinase activity and driving cell entry to S phase. In late G1 – early S 
phase, Cyclin A is expressed which activates CDK2 and then CDK1 in G2 phase (green). In 
late G2 phase, cyclin B is expressed activating CDK1 (yellow), further increasing total kinase 
activity and driving cell entry to mitosis (Hochegger et al., 2008). 
 
CIZ1 is an important part of the control and promotion of DNA replication. CIZ1 contacts pre-
RC through direct Cdc6 interactions (Copeland et al., 2015). CIZ1 also interacts directly with 
cyclin A and cyclin E, coordinating their functions within the nucleus. CIZ1 interacts with cyclin 




E in mid G1 phase and is displaced by cyclin A at the G1 – S transition, helping to ensure that 
they execute their functions in the replication initiation process sequentially in the same place 
(Copeland et al., 2010). This does not occur when CIZ1 is either mutated or depleted via 
siRNA (Copeland et al., 2010). Taken together, this supports the proposal that CIZ1 
contributes to the delivery of cyclin-CDK2 complexes to the origins of replication (Copeland et 
al., 2015). 
 
CIZ1 is also a CDK sensor that promotes initiation of DNA replication and prevention of re-
replication (Copeland et al., 2015). Promotion of initiation of DNA replication occurs at low 
kinase levels, when in a hypophosphorylated state that is permissive for cyclin A–CDK2 
interaction and delivery to licensed origins, whereas delivery to licensed origins is blocked at 
higher kinase levels when CIZ1 is phosphorylated (Copeland et al., 2015). Phosphomimetic 
mutations within CIZ1 prevent cyclin A-CDK2 binding and its replicative function (Copeland et 
al., 2015). 
 
1.3.3 Role of CIZ1 in tumourigenesis 
Deregulation of CIZ1 expression, splicing and activity has been implicated in different cancer 
types, including four of the most common: breast, prostate, colorectal and lung cancers that 
constitute >50% of cancer incidence in the UK. The main mechanisms that studies have 
shown CIZ1 are involved are overexpression, regulation of transcription and alternative 
splicing. 
CIZ1 promotes cellular proliferation in vivo and in vitro; (Copeland et al., 2010, Copeland et 
al., 2015) and can induce tumour formation in mouse xenograft models (Higgins et al., 2012), 
suggesting that CIZ1 can facilitate tumour growth. CIZ1 enhanced tumorigenesis in a number 
of tumours including breast (den Hollander et al., 2006), colorectal (Yin et al., 2013, Wang et 
al., 2014), hepatocellular carcinoma (Wu et al., 2016), gall bladder (Zhang et al., 2015), 
prostate (Liu et al., 2015), small cell lung and non-small cell lung carcinoma (Higgins et al., 




2012). In each case, CIZ1 has been implicated directly in tumour growth due to overexpression 
or alternative splicing (Higgins et al., 2012, Swarts et al., 2018). CIZ1 also has potential for a 
tumour suppressor role. Deletion of CIZ1 has no defects on murine development, but results 
in an increased risk of viral transformation and tumour growth (Nishibe et al., 2013) and 
increased risk of lymphoblastic tumours in aged mice (Ridings-Figueroa et al., 2017).  
 
CIZ1 displays oncogene like functions when overexpressed. Increased CIZ1 expression 
promotes tumour growth and migration. One example of this is overexpression of CIZ1 in 
breast cancer, where CIZ1 aids recruitment of the oestrogen receptor (ER) complex to the 
target gene, resulting in enhanced ER transactivation activity. Subsequently, CIZ1 confers 
oestrogen hypersensitivity, therefore resulting in an increased rate of cellular proliferation (den 
Hollander et al., 2006). Additionally, CIZ1 overexpression has shown to promote tumour 
growth both in vivo and in vitro in hepatocellular carcinoma (HCC) cells. CIZ1 interacts with 
transcriptional factor Yes associated protein (YAP), positively regulating the YAP/Tafazzin 
(TAZ) signalling pathway. Overexpression of CIZ1 lead to an increased interaction between 
YAP/Transcriptional enhancer factor TEF (TEAD) and increased signalling of YAP/TAZ 
transcription factors, which in turn promoted growth and migration of HCC cells via increased 
expression of cyclin E and connective tissue growth factor (CTGF) (Wu et al., 2016, Lei et al., 
2016). 
 
A CIZ1 splice variant (b-variant), with alternative splicing between exon 14 and 15, was 
identified in small cell and non-small cell lung cancers. This variant is restricted to the tumour 
cells, and shRNA that reduces its expression resulted in a reduction in tumour size in xenograft 
models, making it an excellent potential biomarker candidate for lung cancer (Higgins et al., 
2012, Coverley et al., 2017). Additionally, the alternative splicing of CIZ1 in exons 8-12 has 
been identified in early-stage solid tumours of breast and colon cancers (Swarts et al., 2018). 
Alternative splicing of exon 4 in Ewing tumour was found to influence the spatial distribution 




of the CIZ1 protein within the nucleus, which raises the possibility that CIZ1 alternative splicing 
could influence organised patterns of DNA replication (Rahman et al., 2010, Rahman et al., 
2007). The precise role of each splice variant has yet to be determined, but they may influence 
CIZ1 function or stability contributing to tumorigenesis. 
 
1.4 Aims  
There is a direct link between CIZ1 overexpression in multiple tumour types. The aim of the 
current work is to investigate whether CIZ1 is detectable and/or differentially expressed in 
glioblastoma. In addition, this project will assess if CIZ1 expression is required for proliferation 
in neurological tumours. The work will be separated into 2 parts. The first will assess the 
viability of CIZ1 as a biomarker using FFPE glioblastoma tumours to determine CIZ1 staining 
pattern and localisation, comparing healthy and tumour areas. In addition, primary 
glioblastoma cell line BTNW914 will be compared with U87MG and a glial cell line SVGp12 to 
compare CIZ1 localisation in vitro. The second goal is to establish if CIZ1 contributes to 
glioblastoma proliferation by establishing transfection procedures to deplete CIZ1 using 
siRNA. Finally, the pharmacological reduction of CIZ1 levels through the inhibition of CDK or 
DDK kinases will be evaluated. 
  



























Chapter 2: Methods and Materials 
  




2.1 Cell Culture  
SW620 (colorectal cell line) and U87MG (glioblastoma cell line) cells were cultured using 
Dulbecco’s modified eagle medium (1 g/l glucose, with pyruvate and GlutaMAX I™) (DMEM) 
(GIBCO). SVGp12 cells (transformed glial cell line) were cultured using Eagle’s minimal 
essential medium (EMEM) (Lonza). BTNW914 primary glioblastoma cells were cultured using 
F10 Ham’s media. All media were supplemented with 1 % v/v penicillin, streptomycin, 
glutamine (100 X) (GIBCO) and 10 % (v/v) foetal bovine serum (FBS) (Labtech). Cells were 
grown in 15 cm diameter dishes in 30 ml of media or 10 cm diameter dishes with 10 ml media. 
Cells were incubated in a ThermoFisher Scientific HeracellTM 150i, at 37 °C in 5 % CO2.  Cells 
were passaged every 2-3 days and maintained at 70% confluency. Media was discarded from 
cells and cells were rinsed in 10 ml Dulbecco’s PBS (GIBCO), then trypsinsed in 9 ml DPBS 
supplemented with 1 ml 0.5% trypsin-EDTA (GIBCO) for 2-3 minutes until cells were released 
from the plates. To protect cells, trypsin was neutralised with an equal volume DMEM and split 
evenly across the desired number of plates and made up to 30 ml with media.  
 
2.2 Primary Cells 
Primary glioblastoma cell lines from the Brain Tumour North West biobank (BTNW914, female, 
aged 67, glioblastoma patient) were established from human glioma biopsies obtained from 
the Brain Tumour North-West (BTNW) tissue bank at Royal Preston Hospital. Cells were 
maintained as described (Section 2.1). 
 
2.3 Antibodies 
A full list of antibodies used in this study are in Table 2.1. Monoclonal antibodies against actin 
(AC15, Sigma Aldrich), and polyclonal antibodies against, histone H3 (Abcam, ab1791) were 
used as directed for Western blotting and/or immunofluorescence. CIZ1 was detected with a 
rabbit polyclonal antibody raised against purified bacterially expressed recombinant ECIZ1‐




N471 for this study (Covalab) (Pauzaite, 2019). For Western blots, goat anti‐mouse‐IgG 
conjugated to peroxidase (POD) (Sigma Aldrich) and goat anti‐rabbit‐IgG–POD (Sigma 
Aldrich) were used with an ECL detection system (GE Lifescience). For immunofluorescence, 
Alexa‐Fluor®‐488‐conjugated goat anti‐mouse‐IgG (H+L) (A10667) (Invitrogen) were used. 
Phosphospecific anti‐CIZ1 phospho‐T293 (anti‐pT293) was produced by immunisation of 
rabbits with TAPKQTQTpTPDRL peptide, where pT indicates phosphothreonine (Copeland 
2015 Covalabs). Antibodies were purified by sequential subtraction on unphosphorylated 
peptide columns and enrichment on a phosphopeptide column, to purify phosphospecific anti-
CIZ1 antibodies (Pauzaite, 2019). 
Table 2.1: Antibodies used in this study. Supplier details, concentration used, species 
used, and conjugate indicated. 
Antibody 
Target 
Supplier Code Dilution Antibody 
species 
Conjugate 
β-Actin Sigma Aldrich A-1978 1/5000 Mouse N/A 
Histone H3 Abcam ab1791 1/10000 Rabbit N/A 
MCM2 (BM28) BD 
Biosciences 




C valabs Copeland 
et al. 2015 
1/1000 Rabbit  
pCIZ1 - T293 Covalabs Copeland 
et al. 2015 













Abcam Ab7051 1/5000 Goat HRP 




2.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE)   
Protein fractions were analysed by resuspension of cell fraction at a 1 in 4 ratio 4x SDS PAGE 
loading buffer (200 mM tris HCl pH 6.8, 27.7 mM SDS, 40% (v/v) glycerol, 1 mM DTT) and 
boiled for 10 minutes. Samples were loaded onto hand poured 10 % SDS-PAGE gels using 
the Mini-PROTEAN Tetra Cell System (BioRad) in Tris glycine SDS solution (TGS) (250 mM 
tris, 1.92 M glycine, 1% (w/v) SDS) between 100 V and 200 V for 1 hour. Gels were analysed 
by Western blotting.  
 
2.5 Western Blotting  
After SDS-PAGE gels were soaked in transfer buffer (composition). Protein was transferred 
onto an Amersham Protran 0.45 nitro-cellulose membrane (GE Life Sciences) or 
polyvinylidene fluoride (PVDF) membrane (GE Life Sciences) using a semi dry transfer 
system. Filter paper, nitrocellulose/PVDF membrane and gels were all soaked in transfer 
buffer (750 µM tris base (SIGMA), 10 µM CAPS (SIGMA), 0.01% (w/v) SDS, 10% (v/v) ethanol 
(Fisher)). Four layers of filter paper were stacked, followed by the nitrocellulose/ transfer 
membrane, gel and then four more layers of filter paper. Protein was transferred at 1 mA/cm2 
of membrane for one and a half to two hours. Membranes were blocked in 10 ml blocking 
buffer (1% (w/v) BSA (Biowest), 0.05 M Tris, 0.138 M NaCl, 0.0027 M KCl, pH 8.0, 0.1% (v/v) 
TWEEN 20 (Sigma Aldrich)) for one hour. Membranes were incubated with specific primary 
antibody (Table 2.1) overnight at 4 °C. Blots were washed four times for five minutes in 5 ml 
blocking buffer. Blots were incubated with secondary antibody for one hour. Blots were 
washed four times for 5 minutes in 5 ml washing buffer (0.05 M tris, 0.138 M NaCl, 0.0027 M 
KCl, pH 8.0, 0.1% (v/v) TWEEN 20) prior to imaging. Blots were developed using the BIO-
RAD ChemiDoc™ MP system.  
 




2.6 Standardising Protein Loads 
Protein loads were standardised using actin or histone H3 load using quantitation of band 
intensities using the BIO-RAD Image Lab Software. 5 µl of sample was ran on SDS-PAGE 
and transferred to a nitrocellulose membrane. Membranes were probed for their load control 
and developed. Loading was adjusted across samples to ensure uniform load control band 
intensity. The band intensity was converted into relative number by dividing the protein band 
number by the actin band number to give relative quantity. The control was then equalised to 
1 and every sample was divided by the relative control number showing relative variation from 
control. 
 
2.7 Drug treatments 
Asynchronous cell populations at 50-70% in confluency, were treated with small molecule 
CDK2, CDK4/6 or DDK inhibitors as indicated (Table 2.2) either 7 hours or 24 hours prior to 
cell harvesting. These timepoints were selected to represent an acute and long timepoint, with 
the acute 7 hour timepoint capturing cells in different phases of the cell cycle, and the 24 hour 



















CDK4/CDK6 10μM Sigma Aldrich 
PHA-767491 
dihydrochloride 
Cdc7 10μM Sigma Aldrich 
XL-413 hydrochloride Cdc7 10μM Selleckchem 
Roscovitine CDK2 30μM Sigma Aldrich; 
Selleckchem 
CVT-313 CDK2 10μM Santa Cruz 
Biotechnology 
Table 2.2: Small molecule kinase inhibitors used in this study. Small molecule, supplier, 
concentration and provider is listed.  
 
 
2.8 Flow Cytometry  
Cells were pulse labelled with EdU one hour prior to harvest. Cells were harvested by 
trypsinisation followed by centrifugation at 500 x g. EdU labelled cell pellets were washed (with 
centrifugation between each step for 5 min, 500 x g).  3 x with 500 µl 1 % BSA in 1 x PBS, 
fixed with 4% PFA for 15 min, washed 3 x with 1% BSA, permeabilised with 0.5% Triton X-
100 for 20 minutes, and washed 2 x with 1% BSA. Cells were protected from light and 
incubated for 30 minutes on ice with Click-iT™ EdU Cell Proliferation Assay Cocktail 
(Invitrogen) containing Alexa Fluor 488 or Alexa Fluor 566. Cells were washed 2 x with 1% 
BSA and 1 x with PBS and stained with 100 µg/ml of Propidium Iodide in 0.1% Triton X-100 
in PBS. Cells were analysed with Beckman Coulter CytoFLEX using FITC (525/40) and PE 
(585/42) channels. Data were collected for ~10,000 cells with consistent gating applied for all 
samples. 
 




2.9 Determination of Percentage S-phase Cells by Ethynyl 
Deoxyuridine (EdU) Incorporation 
An hour before harvesting, cells were pulse labelled with 1 µM EdU (Invitrogen). Cells were 
fluorescently labelled using the protocol outlined in the click-iT® EdU imaging kits protocol 
(Invitrogen). Coverslips were mounted in Vectashield with DAPI (Vector Laboratories). 
Percentage of cells in S phase was calculated using a Zeiss LED illuminated microscope and 
counting the fraction of DAPI labelled nuclei that had fluorescently labelled replication foci 
(alexafluor-488). Only nuclei with replication foci that were present throughout the nuclei were 
scored positive. Percentage of cells in S phase cells was calculated using Microsoft Excel to 
calculate percent positive for each experiment. 
 
2.10 Nucleofection of cell lines 
Depletion of cells lines was performed using the Nucleofector™ 2b system (Lonza). BTNW914 
were transfected with anti-CIZ1 siRNA (s24489) in Cell Line Nucleofector® Solution for 
Primary Mammalian Glial Cells (Amaxa® Basic Nucleofector® Kit for Primary Mammalian Glial 
Cells; Lonza protocol). Nucleofector® programs A-033, E-013, G-013, O-017 and T-020 were 
selected for transfection optimisation according to manufacturer’s optimisation protocol using 
GFP, then program T-020 was used thereafter following transfection optimisation. The 
composition of the transfection reagent and current/voltage settings are proprietary and are 
not freely available. The cells were harvested after 24 hours for protein and RNA analysis, and 
24, 48, and 72 hours for flow cytometry analysis as indicated in the figures. 
 
2.11 RNA extraction and qPCR 
Cells were harvested and their total RNA was purified using PureLink® RNA Mini Kit (Invitrogen) 
according to providers instructions. RNA was first quantified using Nanodrop (ThermoScientific). 
Then quantitation of transcript abundance was performed using SuperScript™ III Platinum™ 




One-Step qRT-PCR Kit (Invitrogen) using 25 ng of total RNA and primers for CIZ1 
(Hs00967155) and GAPDH (Hs02758991) using a FX96 Touch™ Real-Time PCR Detection 
System (BIO-Rad). Program used: 42−60°C, 95°C for 2 minutes hold, 40 cycles of 95°C - 15 
seconds, 60°C - 30 seconds. Relative expression was calculated as a mean fold change of 
the difference between control gene ct and the gene of interest ct,(delta ct) then all results 
divided by control results.  
 
2.12 Sub-Cellular Fractionation 
Cells were scrape harvested, and cell debris volume determined. All steps were performed on 
ice. The total volume was made up to an equivalent volume for all samples in PBS, 1mM EDTA, 
1x complete protease inhibitor cocktail (Roche) and 1 mM DTT. Half of the sample was 
immediately taken as the total protein fraction. The remaining half was centrifuged at 5000 x g 
for 5 minutes. The resulting supernatant was the cytosolic/nucleosolic fraction and pellet was 
chromatin fraction. All fractions were resuspended in a 1 in 4 ratio 4x SDS PAGE loading buffer 
(200 mM tris HCl pH 6.8, 27.7 mM SDS, 40% (v/v) glycerol, 1 mM DTT). Samples were stored 
at -20 °C until use. 
 
2.13 Immunohistochemistry of BTNW patient samples 
Formalin fixed paraffin embedded (FFPE) tumour sections were provided by Preston Royal 
Hospital. Patient samples provided had been prepared to the point of paraffin removal. These 
samples include: BTNW2265, BTNW2803, BTNW2819, BTNW2424, BTNW2422 and 
BTNW2430. 
 
2.13.1 Antigen Retrieval 
Sections were dewaxed in xylene, taken to absolute alcohol, then washed under running tap. 
A pressure cooker was filled with 1.5L of 0.01 M citrate buffer pH 6.0 (0.02 M Citric Acid 




Crystals, 0.05 M NaOH) and brought to boil inside the microwave, lid on but not fully closed. 
Slides placed in the heated buffer within the pressure cooker, fully sealing the lid. Heated in 
microwave until pressure cooker valve had risen. Once risen, heated for a further 2 minutes. 
Allowed pressure cooker to cool until valve had dropped. Slides were then removed and rinsed 
in warm tap water, gradually introducing more cold water for 10-15 minutes. Then proceeded 
with immunostaining. 
 
2.13.2 Immunostaining using the Vectastain Elite Universal ABC Kit 
Immunostaining of tumour sections was conducted using the VECTASTAIN® Elite® ABC 
Universal Kit Peroxidase (VECTORLABS). Sections were washed under running tap water. 
Sections were rinsed with pH 7.4 TBS (500 ml of distilled water, 0.05 M Tris HCL, 0.079 M 
Sodium Chloride, 1% w/v Bovine Serum Albumin). Back of slide was dried and placed on 
immunostaining tray. Area around section was dried, and Dako hydrogen peroxide blocking 
reagent was placed on the sections for 5 minutes. Slides were drained and washed with TBS. 
Slide was dried around the tumour section. VECTASTAIN® Blocking Serum was added to 
sections for 20 minutes, then drained and dried. Primary antibody was placed on slides, and 
left overnight at 4°C. The following day, slides were washed in TBS, and incubated in 
VECTASTAIN® Biotinylated Universal Antibody for 30 minutes. Slides washed in TBS. 
Samples were then incubated VECTASTAIN® StreptABComplex/HRP Solution for 30 
minutes, then washed in TBS. One drop of DAB chromogen was added to 1ml of Dako 
substrate buffer and placed on sections for 10 minutes. Slides were washed in running water, 
counterstained in haematoxylin for 5 seconds, then washed immediately in hot running water 
until water ran clear from blue staining. Slides then dehydrated in alcohol, soaked in xylene 
and mounted in styrolite. 
 




2.14 Ethics Statement for use of Patient Samples and Primary Cells 
Ethical approval and informed consent was obtained by East of England - Cambridge East 
Research Ethics Committee for the use of human tissues to the Brain Tumour North West 
(BTNW) research bank (Approval reference no. 14/EE/1270). A confirmation letter was issued 
to the BTNW research bank stating the approval of participants written consent form for the 
collection of tumour and non-cancerous brain tissues for future use. The current study was 
approved by the Brain Tumour North West research committee for the use of tissue sections 






























Chapter 3: Determination of CIZ1 









A biomarker should be specific and sensitive to the tumour type and be able to discriminate 
between healthy and diseased states. Biomarker specificity is the proportion of subjects 
without the target condition in whom the test result is negative, whereas biomarker sensitivity 
is the proportion of subjects with the target condition in whom the test result is positive 
(Mazzone et al., 2017). There are a handful of diagnostically useful biomarkers currently for 
glioblastoma, however, they lack both the sensitivity and specificity required. The most 
clinically relevant diagnostic biomarkers are IDH1/2 mutation, MGMT promoter methylation, 
and EGFR amplification/mutation (Szopa et al., 2017). IDH1/2 is mutated in almost all 
secondary glioblastomas, making it diagnostically relevant. The drawback being, only 10% of 
glioblastoma cases are secondary, making this biomarker ineffective at diagnosing 90% of 
cases. However, this selectivity provides prognostic information and can also guide treatment 
for this subgroup.  
 
Methylated MGMT promoters are present in about 40% of glioblastoma cases and is used to 
distinguish true progression and pseudoprogression in patients with newly diagnosed 
glioblastoma (Szopa et al., 2017). This is also a useful prognostic marker as patients with 
MGMT promoter methylation have significantly improved response to the TMZ treatment. 
Again, this biomarker leaves 60% of cases undiagnosable. EGFR amplification is seen in 
approximately 40% of cases, and is often associated with high-grade tumours in the Classical 
subgroup (Verhaak et al., 2010). Additionally, approximately half of patients that present with 
EGFR amplification have a constitutively active mutation due to deletion of exons 2-7 
(EGFRvIII) that is absent in patients without EGFR amplification. Prognostically, overall 
survival in patients with this EGFRvIII mutation is improved, particularly in combination with 
non-mutated PTEN, methylated MGMT promoter and <20% Ki64 levels (Szopa et al., 2017, 
Montano et al., 2011). Together, these biomarkers can build up a picture that can lead to a 
glioblastoma diagnosis and ruling out of other gliomas. 




However, due to the lack of a specific biomarker in glioblastoma diagnosis, finding a biomarker 
that is able to distinguish between healthy and characteristic glioblastoma brain tissues would 
be of clinical significance.  
 
3.2 Immunohistochemistry using polyclonal CIZ1 antibodies 
3.2.1 Antibody Optimisation 
Here, CIZ1 levels are determined in FFPE glioblastoma tumours from the BTNW biobank. The 
optimisation of a novel polyclonal anti-CIZ1 antibody is used to stain sections. Expression, 
localisation and cell types that are stained are determined. Initially, an antibody titration was 
performed to determine the optimum concentration of CIZ1-N471 immunopurified antibody to 
use, that would allow observation of CIZ1 staining without non-specific background staining. 
Sections were prepared by staff at Preston Royal Hospital to the point of paraffin removal. 
From here, antigen retrieval and immunostaining were undertaken to label sections with CIZ1-
N471 immunopurified antibody, stained with DAB and counterstained with haematoxylin. CIZ1 
antibody concentrations used ranged from 1:50 to 1:800 using patient sample BTNW2803.  
Two images taken at each concentration: one from a non-tumour section (left column) and the 
other from a section at the intersection of tumour and non-tumour (right column) (Figure 3.1). 
The left column clearly shows a reduction in the brown DAB stain as the antibody 
concentration reduces, whereas the right column shows the DAB stain reduces in healthy 
tissue but remains in the tumour demonstrating antibody selectivity and specificity. From these 
results, the staining seen at the 1:800 concentration of CIZ1 antibody shows the highest 
degree of specific staining, with minimal background stain. Therefore, this concentration was 
used to label all subsequent sections. 





Figure 3.1: Optimisation of CIZ1 antibody for immunohistochemistry. Glioblastoma 
patient sample BTNW2803. CIZ1 dilutions of 1:50-1:800 were used. A. Images taken of 
normal cortex. B. Images taken at an intersection between tumour and non-tumour tissue. 
DAB stained (brown) with haematoxylin counterstain of nuclei (blue). Scale bars are shown 
by black bars in bottom right of image. 




3.2.2 Observed CIZ1 staining in normal tissues is limited to specific cell types 
In order to identify the CIZ1 staining patterns seen within tumour sections, the staining patterns 
seen within the normal tissue sections that surround the tumour areas were analysed. Firstly, 
we looked within the cortex of the samples and observed CIZ1 staining in neuronal cells 
(Figure 3.2). In each case, the cells’ projected axons are facing towards the brain surface.  
Interestingly, the neurons in these patient samples stained with CIZ1 both in the cytoplasm 
and nucleus. Notably, oligodendrocytes are not efficiently stained, as a single oligodendrocyte 
can extend its processes to 50 axons, therefore would be visible spanning across neurones. 




Figure 3.2: CIZ1 staining of neurons in healthy tissue. Black arrows pointing out examples 
of neurons being stained positively for CIZ1. Neural axons point towards cortex surface. DAB 
stained (brown) with haematoxylin counterstain of nuclei (blue). Scale bars are shown by black 
bars in bottom right of image. A. Image of neurons within healthy cortex of patient sample 




There was also consistent staining of endothelial cells. From the patient samples, it appears 
that endothelial CIZ1 staining occurs exclusively in the tumour region, whereas no CIZ1 
staining is seen in the endothelial cells in the normal tissue areas (Figure 3.3). Although the 
tumours sections imaged here show this relationship, it remains to be determined that this is 
a consistent feature for CIZ1 staining across a larger sample size of patients. 





This observation could be explained by the production of VEGF by growing tumours, reported 
widely. Glioblastoma is characterised by increased vascularisation due to tumour induced 
angiogenesis by localised over overproduction of VEGF in the  tumour (Linkous and 
Yazlovitskaya, 2011). As CIZ1 has a role in the efficiency of DNA replication and its expression 
increases through the cell cycle, this increased staining may reflect a more proliferative 
phenotype for endothelial cells and tumour cells. 
 
Figure 3.3: Differential staining of endothelial cells. Sections were DAB stained (brown) 
with haematoxylin counterstain of nuclei (blue) from 3 patients as indicated. Black arrows 
indicate endothelial cells and scale bars are shown by black bars in bottom right of image. 
A+C. Endothelial cells without CIZ1 staining within a non-tumour area. B+D. Numerous 
endothelial cells within a tumour area all positively stained for CIZ1. 
 
3.2.3 Basic cancer morphology 
Next, to observe CIZ1 expression and localisation within tumour samples, 6 patient samples 
were imaged. A common observation between the patient samples was the consistent staining 




within gemistocytes. Gemistocytes are a type of GFAP expressing astrocyte, which in 
response to a stressor, has retracted its processes and has swollen to become globose in 
shape, resulting in the nucleus being pushed to the edge of the cell (Avninder et al., 2006). 
Figure 3.4 shows examples of these gemistocytic astrocytes, some of which are indicated by 
black arrows. Significantly, there is clear CIZ1 staining within the cytoplasm, that is uncommon 
in tissues where immunofluorescence has been used to determine subcellular localisation, 
where CIZ1 is predominantly nuclear even when overexpressed with a GFP reporter 
(Ainscough et al., 2007, Coverley et al., 2005). However, within the tumour there is an increase 
in cytoplasmic CIZ1 stain, and the functional consequences associated with the mis-
localisation has not been determined.  
 
 
Figure 3.4: CIZ1 staining of gemistocytic astrocytes. Black arrows indicate gemistocytes, 
globose in shape with nucleus pushed to edge and retracted processes. DAB stained (brown) 
with haematoxylin counterstain of nuclei (blue). Scale bars are shown by black bars in bottom 
right of image. A. Image of tumour section of cortex, highlighting staining of gemistocytic 
astrocytes of patient sample BTNW2265 where both nucleus and cytoplasm are stained. B. 
Image of tumour section of cortex, highlighting staining of gemistocytic astrocytes of patient 
sample BTNW2265 demonstrating cells where only cytoplasm is stained. 
 
Oedema is another common characteristic of cancer and predicts poor clinical outcome in 
glioblastoma (Wu et al., 2015). High amounts of oedema were found within tumour sections 
of different patient samples (Figure 3.5).  





Figure 3.5: Oedema within tumour section. Oedema indicated by black arrows and scale 
bars shown with black bars. DAB stained (brown) with haematoxylin counterstain of nuclei 
(blue). Scale bars are shown by black bars in bottom right of image. A. Image of oedema 
within tumour section of cortex of patient sample BTNW2265. B. Image of oedema within 
tumour section of cortex of patient sample BTNW2424. 
 
Centrosome amplification occurs frequently in almost all types of cancer, and is considered 
as the major contributing factor for chromosome instability in cancer cells (Fukasawa, 2005).  
Healthy cells normally have two centrosomes, which allows the usual bipolar segregation of 
chromosomes along a single plane during mitosis. The production of multiple centrosomes in 
some cancer cells can result in a multipolar segregation, leading to the production of either 
non-viable cells or aneuploid cells (Fukasawa, 2005, Bose and Dalal, 2019). Figure 3.6 shows 
at least two examples of this multipolar segregation (black arrows) that is characterised by 
loss of chromosomal organisation along a single plane, with chromosomes being pulled in 3 
or more planes. However, whilst these cells do show DNA staining reminiscent of multipolar 
mitoses, the cells themselves are so large they are almost certainly a different cell type to 
most cells in this image. The size and appearance of the cells suggest possible immune 
infiltration. The presence of immune infiltrate in gliomas is common, but it is still in debate as 
to whether this affects prognosis positively or negatively, and may be dependent on different 
immune cell microenvironments (Domingues et al., 2016). Figure 3.6 has also captured 
numerous mitoses taking place, another characteristic of cancer, representing the rapid and 
uncontrolled division that occurs in cancer.  




Mitosis is usually underrepresented in paraffin sections, therefore observing numerous 




Figure 3.6: Multipolar cells are characteristic of glioblastoma. Black arrows indicate 
multipolar cells, where the nuclei are in the process of a multidirectional mitosis. DAB stained 
(brown) with haematoxylin counterstain of nuclei (blue). Scale bars are shown by black bars 
in bottom right of image. 
 
3.2.4 CIZ1 overexpression and specificity in patient IHC samples 
Having established parameters for anti-CIZ1 IHC, the next aim was to determine whether the 
CIZ1 staining was selective for tumour cells over healthy cells. Six glioblastoma FFPE patient 
tumour samples were used and labelled with CIZ1-N471 immunopurified antibody, stained 
with DAB and counterstained with haematoxylin. This revealed that CIZ1 was expressed at 
higher levels  within the tumour and there is a clear quantitative difference in staining within 
and proximal to the tumour (Figure 3.7) that identifies the region where tumour cells meet 
normal brain that is demarcated by the red dashed line. Comparing each side of the 
demarcation for each image, there is a clear difference in both morphology and staining. The 
difference in morphology alone indicates a stark visual contrast, allowing us to have 
confidence that the highly stained area is in fact tumour. In addition, there is an increase in 




CIZ1 staining, and increase in cell density in the tumour region, oedema and mis-localisation 
of CIZ1 protein to the cytoplasm. These features are common to each of the six patient 
sections, but the levels of CIZ1 expression are variable. These data suggest increased CIZ1 





Figure 3.7: Representative anti-CIZ1 IHC of FFPE sections. Differential CIZ1 staining at 
tumour intersection. Red line shows the demarcation between normal and tumour tissue. DAB 
stained (brown) with haematoxylin counterstain of nuclei (blue). Scale bars are shown by black 
bars in bottom right of image. A. Intersection between healthy and tumour section of cortex of 
patient sample BTNW2265. B. Intersection between healthy and tumour section of cortex of 
patient sample BTNW2803. C. Intersection between healthy and tumour section of cortex of 
patient sample BTNW2819. D. Intersection between healthy and tumour section of cortex of 
patient sample BTNW2265. 
 




3.2.5 Micrometastases and Invasion  
Glioblastoma is a highly aggressive tumour type that migrates and invade surrounding and 
distal tissue. Here the migration of the tumour through brain tissue is observed and this 
visualisation is enhanced by the increased contrast provided by CIZ1 staining within 
glioblastoma. An example using BTNW2430 sample is shown in Figure 3.8, which shows an 
example of cancer cells migrating along the pia mater (red arrow). The brain surface is 
comprised of six distinct layers, with the pia mater being the innermost. A pia vessel, marked 
by the black arrow, is seen as an invagination from the pia mater layer, that shows increased 
CIZ1 staining in tumour cells invading normal cortex.  
 
Figure 3.8: Brain surface with pia vessel infiltrating from pia mater at two 
magnifications. Red arrows indicate pia mater layer, black arrows indicate the infiltrating pia 
vessel. DAB stained (brown) with haematoxylin counterstain of nuclei (blue). Scale bars are 
shown by black bars in bottom right of image. A.  Image of cortex and cortex surface, showing 
migration of tumour cells along pia mater, and infiltration of cells via pia vessel in patient 
sample BTWN2430. B. Higher resolution image of cortex and cortex surface, showing 
migration of tumour cells along pia mater, and infiltration of cells via pia vessel in patient 
sample BTWN2430. 
 
In addition, there was evidence for the use of anti-CIZ1 IHC can aid in the visualisation of 
micrometastases. Micrometastases are a small collection of cancer cells from the original 
tumour that have spread to another part of the body through the blood or lymph nodes, or in 
some cases, a clonal variant within the tumour, typically less than 2 mm. The ability to identify 
small clusters of metastatic tumour cells would be significant, aiding in clinical staging and 




gauging the aggressiveness of individuals tumour. Anti-CIZ1 IHC was able to identify 
micrometastases from 2 of 6 patients in this study further supporting the potential role for CIZ1 
as a glioblastoma biomarker (Figure 3.9). Here, BTNW2430 shows a large cluster of cells that 
have metastasised from the primary tumour. Importantly, anti-CIZ1 IHC has also been able to 
identify small clusters <50 microns, suggesting that this may be a sensitive approach to 
visualise metastatic disease even in very small clusters (BTNW2819). 
 
Figure 3.9: Areas of tumour heterogeneity within a glioblastoma tumour area. Area 
within the red line demarcation represents the clonal variant. DAB stained (brown) with 
haematoxylin counterstain of nuclei (blue). Scale bars are shown by black bars in bottom right 
of image. A. Macrometastasis of clonal variant within tumour section of brain cortex taken from 
patient sample BTNW2430. B. Micrometastasis of a small cluster of clonal variant cells within 
brain cortex taken from patient sample BTNW2819. 
 
3.3 Localisation and expression of CIZ1 in neural cell lines 
3.3.1 Fractionation of neural cell lines 
An unexpected observation from patient samples was the mis-localisation of CIZ1 to the 
cytoplasm of tumour cells in each of the 6 patient FFPE sections (Figure 3.4). CIZ1 is 
predominantly nuclear in murine and human cell lines, even when expressed ectopically 
(Ainscough et al., 2007, Copeland et al., 2010, Copeland et al., 2015, Coverley et al., 2005). 
This mislocalisation could be a feature of its deregulation in glioblastoma. To assess whether 
there are detectable changes in CIZ1 localisation, transformed glia (SVGp12), glioblastoma 
cell lines (U87MG) and primary BTNW914 glioblastoma cell lines were used. Cellular 




fractionation was performed producing nuclear and cytoplasmic fractions to confirm whether 
what was observed in the brain tumour IHC samples would be recapitulated in vitro. Fractions 
from primary cell line BTNW914 were collected, alongside cell line U87MG and normal cell 
line control SVGp12. Unfortunately, it proved difficult to produce images with all fractions 
beside each other due to differing levels of proteins in each fraction, making it difficult to make 
direct comparisons.  However, we were still able to compare CIZ1 levels within each cell type 
and its localisation. In SVGp12, BTNW914 and U87MG cell lines, CIZ1 is present in both the 
cytosolic and nuclear fractions, which is consistent with what was observed from the IHC 
patient glioblastoma sections. Consistently, the lower CIZ1 band from the nuclear fraction was 
missing or significantly reduced. Surprisingly, while the cytosolic CIZ1 fractions of the 
BTNW914 and SVGp12 exhibit a very similar pattern in the CIZ1 bands, the U87MG cell 
cytosolic fraction exhibits loss of the top band. The multiple bands seen may be due to a splice 
variation, which have been discovered in other cancers (Coverley et al., 2017, Rahman et al., 
2010, Swarts et al., 2018), or possibly a post-translational modification (PTM). These data 
suggest that CIZ1 is localised both in the nucleus and the cytoplasm. The limitation of this 
approach is that we are unable to monitor cell to cell variation that can be determined using 
microscopy methods. In addition, permeabilisation of the nuclear membrane releases 
nucleosolic CIZ1 pools that may confound interpretation in cellular fractionation studies. 
 





Figure 3.10: Fractionation of neural cell lines. BTNW914, U87MG and SVGp12 cells were 
split into fractions of total protein (TP) cytosolic (C) and nuclear (N). Western blot was probed 
for CIZ1 and Actin for cytosolic fraction and CIZ1 and H3 for nuclear fraction.  
 
3.3.2 Immunofluorescence of neural cells 
To complement the fractionation approach and to visualise CIZ1 expression and localisation 
within individual cells, immunofluorescence confocal microscopy was used. Initially, to 
determine the optimum CIZ1 antibody concentration in BTNW914 cells, 2-fold dilutions were 
performed, with concentrations ranging from 1:200 to 1:1600. Images were taken using an 
epifluorescence microscope using different filters to view either CIZ1 staining using Alexafluor-
568, or nuclear staining using DAPI. With all concentrations used, cytoplasmic staining is 
visible, with the optimal anti-CIZ1 antibody dilution found to be 1:400 (Figure 3.5).  
 





Figure 3.11: Optimisation of CIZ1 antibody for immunofluorescence with BTNW914 
cells. Representative immunofluorescence images of BTNW914 cells treated with CIZ1 









Figure 3.12: Optimisation of CIZ1 antibody for immunofluorescence with SVGp12 cells. 




Two CIZ1 foci appear frequently within the BTNW914 nuclei that were produced from a female 
patient. The large clusters of CIZ1 within the nucleus were reminiscent of CIZ1 localisation 
with the inactive X-chromosome and its role in X chromosome inactivation with Xist. One study 




found a very similar staining pattern of CIZ1 foci within the nucleus, and determined the 
relationship between CIZ1 and Xist (Sunwoo et al., 2017).  
 
 
Figure 3.13: Representative immunofluorescence images of BTNW914 and SVGp12 
cells. Representative immunofluorescence images of cells treated with CIZ1 antibody 
dilutions of 1:800.  
 
Images of each cell type were taken at higher magnification to allow comparison (Figure 3.13). 
The images taken represent different observed CIZ1 expression patterns. The localisation of 
CIZ1 in ‘normal’ SVGp12 cells is both nuclear and cytosolic, all displaying similar patterns of 
expression. On the contrary, CIZ1 localisation patterns in BTNW914 differ from each other in 
these images. Varying levels of cytosolic expression is seen. The two foci seen in the 
BTNW914 cells previously are clear in two of the BTNW914 cells here. However, the cell in 
the third BTNW914 column displays an increased level of expression, with a more disperse 
distribution of foci, not the two distinct foci as seen in the other examples.   
 




3.4 Chapter Discussion 
3.4.1 CIZ1 appears be a biomarker for glioblastoma and identifies tumour 
margins and micrometastasis.  
CIZ1 has been used as a biomarker in lung cancer (Higgins et al., 2012, Zhou et al., 2018). 
CIZ1 was used as circulating biomarker in patients with non-small cell lung cancer (Higgins et 
al., 2012, Coverley et al., 2017). For speed, ease and safety in the diagnostic processes, the 
use circulating biomarkers is beneficial as it only requires taking blood from a patient rather 
than a biopsy. However, the use of CIZ1 as an early circulating biomarker may not be viable 
in with glioblastoma due to the blood brain barrier. However, as the disease progresses, there 
may be detectable CIZ1 in serum after the blood brain barrier is disrupted through 
tumourigenesis.  
 
One of the most important hallmarks of glioblastoma is tumour heterogeneity, from which the 
cancer’s name originates. Not only does intertumoral heterogeneity exist between patients, 
such as what is seen in the aforementioned molecular subtypes (Verhaak et al., 2010, 
Friedmann-Morvinski, 2014), but also heterogeneity within the tumour of a single patient. 
Intratumoural heterogeneity is mostly characterised by distinct genetic alterations that occur 
in individual tumours originating in the same organ. Examples of intratumoural heterogeneity 
were found in some of our own IHC samples (Figure 3.9).  
 
Within one patient sample, a relatively large area of tumour cells was strongly stained for CIZ1 
(Figure 3.9). Even without CIZ1 staining, it would have been apparent in this case that this 
was a tumour metastasis by looking at the density and arrangement of cells. What is 
interesting is the differentially stained within the tumour area.  The large group of highly stained 
tumour cells were amongst other tumour cells that were less stained (Figure 3.9). This 
indicates intratumoural heterogeneity, which in itself, poses a challenge in terms of treatment, 




as it has been described as one of the root causes for therapy resistance (Saunders et al., 
2012). 
 
One study showed that at single cell RNA-sequencing resolution, a single tumour consisted 
of a heterogeneous mixture of cells representing all of the different glioblastoma subgroups 
(Patel et al., 2014). Another study showed that single cell derived glioblastoma subclones 
have distinct genetic identity and maintain differential drug resistance profile (Reinartz et al., 
2017). Interestingly, a recent study has found that glioblastoma recapitulates a normal 
neurodevelopmental hierarchy using single-cell RNA-sequencing, which suggests a possible 
origin for glioblastoma hierarchy, and helps to identify cancer stem cell-specific targets 
(Couturier et al., 2020). 
 
Additionally, CIZ1 was able to detect a micrometastasis within healthy cortex. In this case, 
CIZ1 staining was able to pick up a very small number of cells amongst a large area of healthy 
tissue (Figure 3.9). This micrometastasis would not have been visible on a scan, which 
suggests that CIZ1 could improve the sensitivity of biopsies through identification of metastatic 
disease.  The caveat here is that this tool would not be of use in advanced disease as many 
patients do not experience any symptoms with a small tumour. The average size of a tumour 
upon detection is approximately 3 cm diameter sphere, although this depends on the imaging 
technique and where the tumour is in the brain (Murray, 2012). Also, biopsies are invasive, 
and would not being conducted without evidence of a tumour. MRI is being used increasingly 
to detect brain metastases, and it has shown a significant increase in sensitivity over both 
computed tomography (CT) alone (Hochstenbag et al., 2000, Suzuki et al., 2004) and PET/CT 
(Kruger et al., 2011) for detection of small or asymptomatic metastases. However, the gold 
standard MRI technique of passive contrast enhancement relies on blood–brain barrier (BBB) 
breakdown, an approach that is more sensitive to later-stage metastases (Serres et al., 2012).  
 




Together, these data display not only tumour specificity using CIZ1, but perhaps suggests a 
possible diagnostic role in detecting differences between tumour subtypes. The data we have 
is limited, with no longitudinal data to accompany the patient sample, and a small starting 
sample size. With more patient information, such as what subtype each patient sample 
belongs to, alongside additional patient samples, we may be able to form correlations between 
CIZ1 expression and glioblastoma tumour subtype.  
 
Interestingly, in all 6 patients, CIZ1 staining was seen, albeit at varying levels. One of the 
clinical challenges with glioblastoma diagnosis is that there is not a universal biomarker for all 
subtypes. There is also a lot of overlap in biomarkers used not only between different subtypes 
of glioblastoma, but between other types of brain tumours also. This increases the time from 
biopsy to diagnosis. Having a biomarker that is universally positive for all glioblastoma patients 
would be greatly beneficial in terms of immediately distinguishing it from other brain tumour 
types. It remains to be seen whether CIZ1 has the characteristics to perform as a biomarker 
of specific subtypes or has the potential to detect a range of subtypes. In future, extra controls 
could be performed to test the specificity of the antibody staining such as a blocking peptide 
control for IHC work and siRNA controls for immunofluorescence work in cell lines. 
 
3.4.2 Localisation of CIZ1 
Normally, CIZ1 is localised in the nucleus, where it binds to the nuclear matrix via its nuclear 
matrix anchor domain at the C-terminal, acting as a molecular link between the DNA 
replication machinery and the sub-nuclear structures that organise their function (Ainscough 
et al., 2007, Ridings-Figueroa et al., 2017).  In females, CIZ1 foci are found at X chromosomes, 
as part of its role in X-chromosome inactivation by maintaining Xist RNA localisation. The 
consistent findings of CIZ1 as a nuclear protein is supported by the existence of its nuclear 
matrix anchor domain and its role in both DNA replication and X-Chromosome inactivation. 
 




Throughout this work, a mixture of both nuclear and cytosolic localisation was found. Only one 
other time has cytosolic localisation of CIZ1 been found. When overexpressed individually, 
CIZ1 was mostly localised to the nucleus. However, when co-expressed with p21, this caused 
cytosolic distribution (Mitsui et al., 1999). p21 is a CDK2 inhibitor, which is interesting as when 
we used CDK2 inhibitors, CIZ1 levels decreased. In this case, it does not offer a reasonable 
explanation in line with our observations in later experiments. 
 
The presence of cytoplasmic CIZ1 distribution in an otherwise nuclear protein raises the 
question as to whether this has any implication in terms of disease pathogenesis. Analysis of 
the localisation of CIZ1 in neural cells and glioblastoma cells showed that CIZ1 is localised in 
both the nucleus and cytoplasm in human tissue samples. The cytoplasmic CIZ1 found may 
be the result of translation of CIZ1 protein in the cytoplasm prior to localisation to the nucleus 
or may reflect aberrant localisation associated with disease. Other instances where CIZ1 
localisation is not solely nuclear is when co-expressed with p21, resulting in cytosolic 
distribution (Mitsui et al., 1999), and when CIZ1-F protein expression patterns changed on 
entry to quiescence, switching from nuclear localisation in cycling cells, to nuclear exclusion 
with cytoplasmic signal at confluence, to nearly undetectable in quiescence (Swarts et al., 
2018). In addition, splice variants may lack the nuclear localisation sequence (NLS) that 
prevents transport to the nucleus. This could be determined using RNA sequencing to 
establish the whether these sequences are lost in glioblastoma. Nevertheless, the lack of 
staining found in the nucleus at times was unexpected and may reflect altered functions in 
glioblastoma.  
 
Results of this chapter indicate that CIZ1 appears to be overexpressed in tumour patient with 
glioblastoma, and anti-CIZ1 stain appears to be tumour specific. Going forward, detailed 
stratification of patients and selection based on CIZ1 staining would be useful in determining 
whether CIZ1 IHC staining is representative of all subtypes. This analysis shows that CIZ1 




may be a useful biomarker, as it is able to distinguish between healthy and tumour regions. 
However, at present there is no information regarding the classification of disease. In 
particular, this study does not use representative tumour sections from each of the 4 
classifications of glioblastoma (classical, mesenchymal, proneural and neural). Consequently, 
analysis of a larger patient cohort with full details on classification and molecular biomarkers 
is also required to determine if CIZ1 is a bona fide biomarker in glioblastoma.   
























Chapter 4: Modulation of CIZ1 
expression with CDK and DDK small 
molecule inhibitors.  
  




4.1 Introduction  
Numerous cancers have shown to be dependent on overexpression of CIZ1 for tumour growth 
such as breast, colorectal and prostate (den Hollander et al., 2006, Higgins et al., 2012, 
Nishibe et al., 2013, Pauzaite et al., 2016, Yin et al., 2013, Zhang et al., 2015, Zhou et al., 
2018). The precise mechanism remains to be fully understood, but there appears to be 
adaptions to the cell cycle that makes tumour cells dependent on high levels of CIZ1 in certain 
contexts. The overexpression of CIZ1 appears to be an Achilles heel in this context because 
CIZ1 depletion reduces cancer cell migration, proliferation and tumour growth in xenograft 
models (Higgins et al., 2012, Lei et al., 2016, Wu et al., 2016, Zhang et al., 2015). These 
observations suggest that CIZ1 may be a potential drug target for the treatment of tumours 
with high CIZ1 expression levels. Having established that CIZ1 is overexpressed in 
glioblastoma tumours, therefore may promote proliferation in glioblastoma cells, we shall 
determine whether glioblastoma requires CIZ1 expression for growth. CIZ1 specific siRNAs 
will be used to reduce its levels and determine the effects on proliferation. In addition, it has 
recently been shown that CIZ1 levels can be reduced through the use of small molecular 
kinase inhibitors (Pauzaite, 2019). This approach will be extended to glioblastoma cell lines 
and primary cell lines to establish if CIZ1 levels can be manipulated pharmacologically.  
 
In murine fibroblasts, inhibition of CDK2/DDK activity promotes Ubiquitin/Proteasome System 
(UPS) mediated degradation of CIZ1 (Pauzaite, 2019). This observation suggests that CDK 
or DDK inhibitors may be repurposed to reduce CIZ1 levels through shifting the equilibrium of 
opposing CDK and UPS networks that regulate CIZ1 abundance (Figure 4.1). The model 
proposed suggests that normal CIZ1 levels are regulated via a balance of opposing CDK/DDK 
and UPS networks and by targeting CDK/DDK activity, this may increase the rate of 
proteasomal degradation of CIZ1 (Pauzaite, 2019). Hyperphosphorylation of CIZ1 as a result 
of increased CDK activity may cause over-accumulation, resulting in facilitating increased rate 
of CIZ1 dependent cancer proliferation. Alternatively, CIZ1 may over-accumulate as a result 




of the loss of function of the UPS, which is responsible for normal CIZ1 degradation, in turn 
also contributing to tumourigenesis.  
 
 
Figure 4.1: Model of CIZ1 regulation CDK2 and DDK kinase activity and UPS mediated 
degradation. A. Normal CIZ1 levels are regulated via a balance of opposing CDK/DDK and 
UPS networks. CDK2 and DDK phosphorylation of CIZ1 protects it from degradation, thus 
positively contributing to CIZ1 accumulation in G1 phase. CIZ1 level is downregulated by UPS 
mediated degradation, providing tight regulation of CIZ1 abundance in the cell cycle. B. 
Increased CDK activity may lead to CIZ1 hyperphosphorylation, which in turn leads to CIZ1 
over-accumulation facilitating increased rate of CIZ1 dependent cancer proliferation. C. 
Mutations and loss-of-function in UPS responsible for normal CIZ1 degradation leads to over-
accumulation of CIZ1 contributing to tumourigenesis. Figure adapted from (Pauzaite, 2019). 
 
Although this model predicts that CDK inhibitors may reduce CIZ1 levels, this study will also 
assess the use of DDK and CDK4/6 inhibitors. There is rationale for testing CDK4/6 inhibitors 
as numerous studies have clearly established that the cell cycle kinases CDK4 and CDK6 are 
activated during the pathogenesis of glioblastoma (Michaud et al., 2010, Schroder and 
McDonald, 2015). A phase I study found CDK4/6 inhibitor ribociclib penetrated recurrent 
glioblastoma tissue at concentrations predicted to be therapeutically beneficial. Although well 
tolerated, ribociclib monotherapy seemed ineffective for the treatment of recurrent 




glioblastoma. A phase II trial also found CDK4/6 inhibitor palbocilib monotherapy was not an 
effective treatment for recurrent RB1 positive glioblastoma. However, the patients in this trial 
were heavily pre-treated patients and targeting the CDK4/6 pathway may still deserve further 
exploration (Taylor et al., 2018). There are more promising data showing synergistic efficacy 
of some CDK4/6 inhibitors in combination with other inhibitors, such as mTOR inhibitors 
(Olmez et al., 2017). Additionally, efficacy may depend on tumour subtype, as there is 
evidence that CDK4/6 inhibitors may be increased active inhibition in proneural subtypes (Li 
et al., 2017). Overall, CDK4/6 inhibitors still show promise for effective clinical use. This 
chapter will provisionally evaluate the role of CIZ1 in glioblastoma proliferation firstly through 
use of specific siRNAs, followed by the use cyclin dependent kinase inhibitors (CDKis) and 
DBF4-dependent kinase inhibitors (DDKis). 
 
 
4.2 Transfecting Neural Cells 
4.2.1 BTNW914 transfection optimisation 
Using siRNA to reduce CIZ1 levels is an approach that has been used both in vitro and in vivo, 
successfully causing a corresponding reduction in tumour growth in mouse models (Higgins 
et al., 2012, Liu et al., 2015, Wu et al., 2016) and cellular proliferation in colorectal cancer (Yin 
et al., 2013) and prostate cancer (Pauzaite, 2019) cell lines. The efficacy of this approach in 
previous studies lead to the use of this approach in primary glioblastoma cell lines.  
 
As there was no previously established protocol for BTNW914 primary cells, a transfection 
optimisation protocol was used to determine if nucleofection could be used. Five programs 
were selected in order to optimise and select the program with the best transfection efficiency 
(A-003, E-013, G-013, O-017 and T-020), with a non-transfected control. Cells were 
transfected with GFP, and transfection efficiency was determined using immunofluorescence 




microscopy. Approximately 100 nuclei were counted per transfection program. Of the five 
programs chosen to use for nucleofection, four of the programs (A-003, E-013, G-013 and O-
017) displayed very little transfection efficacy with low GFP percentage (Figure 4.2: B). 
However, program T-020 had a notably higher percentage of 45.5%. As this was found to be 
the most effective transfection program, it was selected to go forward with siRNA experiments.  
  






Figure 4.2: Immunofluorescent images of GFP transfected BTNW914 cells. BTNW914 
transfection optimisation. Cells were transfected with GFP using Nucleofector programs A-
















No transfection 0% 
 
Table 4.1: Percentage of GFP transfected BTNW914 cells per program.  Table with 
percentages of approximately 100 nuclei which were successfully transfected with GFP using 
Nucleofector programs A-033, E-013, G-013, O-017 and T-020, or no transfection.  
 
 
4.2.2 CIZ1 depletion effects  
Having optimised a transfection protocol for BTNW914 cells, the next aim was to determine 
the effect of reducing CIZ1 levels in these cells (Figure 4.3). To ensure CIZ1 had been 
effectively reduced, Western blotting was used to determine protein levels and qPCR 
determine mRNA transcript levels. Western blot analysis displayed a marked reduction of CIZ1 
relative to the control (Figure 4.3: A). In addition, there was also a markedly reduced CIZ1 
mRNA transcript level relative to control samples (Figure 4.3: B). Together, the data show that 









Figure 4.3: Anti-CIZ1 siRNA transfection of BTNW914 cells. Cells were transfected with 
anti-CIZ1 siRNA. A. Cells were harvested after 24 hours. Western blot probed for CIZ1 and 
Actin. B. CIZ1 mRNA levels were quantified by qPCR relative to GAPDH. Data shows the 
mean and standard deviation for 3 technical replicates where n=1. C. Multiparameter flow 
cytometry dot plot showing EdU intensity of nascent DNA (EdU-alexafluor 488) (y-axis) vs 
total DNA (PI) (x-axis).  D. Representative immunofluorescence images showing reduction of 
S phase entry of CIZ1 depleted cells compared to control. E. Percentage of cells in S-phase 
calculated from approximately 100 nuclei using immunofluorescence. F.  Ki67 mRNA levels 
were quantified by qPCR relative to GAPDH. Data shows the mean and standard deviation 
for 3 technical replicates where n=1. G. PrestoBlue proliferation assay performed after 24, 48 
and 72 hours. Data shows the mean and standard deviation for 3 technical replicates where 
n=1. 





Having established that the transfection was successful in reducing CIZ1 transcript and protein 
levels, the next aim was to analyse the effects of CIZ1 depletion on S phase entry in BTNW914 
cells. Samples were analysed by flow cytometry and immunofluorescence. Cells were pulse 
labelled with EdU and fluorescently labelled using the Click-it reaction adding Alexa Fluor (488 
for flow and 555 for microscopy) Azide. This allowed the visualisation of cells that were actively 
replicating their DNA. Using fluorescence microscopy, approximately 100 nuclei were counted 
per sample, counted how many were positively labelled, then calculated a percentage (Figure 
4.3D, E). An 8.1% decrease in EdU incorporation was seen in CIZ1 depleted cells, from 25.8% 
of cells to 17.7% (Figure 4.3: E). This shows there is a decrease in S phase entry of CIZ1 
depleted cells. Flow cytometry analysis of cells pulse labelled 1 hour prior to harvest with EdU 
and counterstained with propidium iodine (PI) was performed on samples harvested after 24 
hours (figure 4.3: C). In contrast to the immunofluorescence data, flow cytometry analysis 
shows slight increase in S phase cells, from 45.65% cells in S phase in the control, to 57.26% 
in the CIZ1 depleted sample. This could simply be explained by the lack of cell numbers in the 
CIZ1 depleted sample, and further replicates are required to ensure reproducibility. 
Alternatively, this could be explained by a reduced rate of DNA synthesis. As this is a measure 
of the percentage of cell s in S-phase and does not necessarily correlate with the rate of cell 
division, a proliferation assay that reports directly on cell number and quantification of the 
proliferation marker, Ki67, was also determined.  
 
Reducing CIZ1 levels in different cancer types reduces in vitro proliferation in numerous other 
cancers (Pauzaite, 2019).  In determining whether BTNW914 glioblastoma cells were 
dependent on CIZ1 for proliferation, Ki67 transcript levels were used as a proliferation marker 
(Figure 4.3: F). In addition, metabolic activity of cells was measured over 72 hours using a 
PrestoBlue assay, which was also used to determine proliferation rate (Figure 4.3: G). qPCR 
results show a reduction in Ki67 mRNA transcript levels relative to control levels, which would 




suggest a reduction in proliferation. A PrestoBlue assay was also performed to determine the 
effects of the CIZ1 depletion on proliferation (Figure 4.3: G). PrestoBlue reagent is reduced 
by metabolically active cells, that provides a fluorimetric change indicative of the number of 
live cells present in a sample. The PrestoBlue reagent was added to each well 1 hour prior to 
inserting into the plate reader. Starting with 5000 cells per well, relative fluorescence levels 
were measured over 72 hours, allowing us to observe the changes in proliferation between 
control and CIZ1 depleted samples. Both the control and depleted sample have similar cell 
numbers at 24h but shows a greater increase in proliferation of control cells over CIZ1 
depleted ones over 72 hours. The data suggest that reduction of CIZ1 appears to slow 
proliferation in this context and further replicates are required here to ensure reproducibility of 
this observation.  
 
4.3 Reduction of CIZ1 levels by CDK/DDK inhibition 
4.3.1 Proof of principle using SW620 cells 
The data presented (Figure 4.3) suggests that reduction of CIZ1 levels may reduce cellular 
proliferation in vitro. As the use of genetic tools to reduce CIZ1 expression is not viable for the 
treatment of glioblastoma, the use of conventional pharmaceutical intervention may provide a 
more suitable approach. The principle for reducing CIZ1 levels by CDKis and DDKis has been 
demonstrated in fibroblasts (Pauzaite, 2019). The aim of using SW620 cells is to validate this 
method, and to test if the outcome can be replicated in multiple cell/cancer types.  
 
Cells were treated with Palbociclib Isethionate (PD0332991, hereafter called PD), PHA-
767491 (PHA), XL-413 (XL), Roscovitine (Ros) and CVT-313 (CVT) to analyse the effects on 
CIZ1 protein levels and site-specific phosphorylation of Ciz1 CDK phosphorylation site T293, 
and to analyse its effect on S phase entry. PD is a currently approved breast cancer treatment 
(Palbociclib) and is a highly selective inhibitor of CDK4 and CDK6 (Fry et al., 2004, De Luca 




et al., 2018).  All inhibitors used here are ATP analogue competitive inhibitors that block ATP 
binding to CDKs through direct competition (Law et al., 2015). Ros inhibits CDKs through 
direct competition at the ATP-binding site. Ros is a broad-range purine inhibitor, which inhibits 
CDK1, CDK2, CDK5 and CDK7, but is a poor inhibitor for CDK4 and CDK6 (Cicenas et al., 
2015). CVT is a potent and specific CDK2 inhibitor, although can also inhibit CDK1 at higher 
concentrations (Brooks et al., 1997). Both PHA and XL are DDKis that affect replication fork 
progression (Rainey et al., 2017, Rodriguez-Acebes et al., 2018), but by differing mechanisms. 
PHA inhibits initiation of DNA replication (Rodriguez-Acebes et al., 2018), whereas XL affects 
fork progression without affecting initiation of DNA replication (Alver et al., 2017). Each kinase 
has off target effects (Table 4.1). 
 













PHA-767491 dihydrochloride  
 




XL-413 hydrochloride  
 
Cdc7 3.4 nM None N/A 
Roscovitine 
 






CDK2 0.5 μM None N/A 
Table 4.2: Summary of small molecule inhibitors used. The table indicates the drugs used 
in the experiments, their main targets and activity expressed as IC50. 
 
Initially as a proof of principle, colorectal carcinoma cells SW620 were treated with CDK4/6 
(PD), DDKis (PHA and XL), and CDK2 inhibitors (Ros and CVT) to analyse the effects on CIZ1 
protein levels and site-specific phosphorylation of CIZ1 CDK site pT293, and to analyse the 
effects on S phase entry. SW620 cells were treated with CDKis and DDKis, then harvested at 
7 hours and 24 hours and probed for CIZ1, pCIZ1, MCM2 and pS53 (Figure 4.6: A). These 




timepoints were selected to represent an acute and long timepoint, with the acute 7 hour 
timepoint capturing cells in different phases of the cell cycle, and the 24 hour timepoint 
allowing observation after a full cell cycle. Western blot analysis for SW620 cells revealed a 
reduction in CIZ1 T293 phosphorylation at both 7 hours and 24 hours for DDKi PHA, and 
CDKis Ros and CVT that resulted in lowered CIZ1 protein levels after 24 hours treatment. This 
may suggest a possible time lag for the effects of reduction in phosphorylation and decrease 
in CIZ1 protein. Importantly, MCM2 levels remained constant that serves as a load control and 
as a DDK specific phospho-site (pS53) that was only reduced by DDK inhibitors PHA and XL. 
 
To analyse the effects of CDKi and DDKi on S phase entry in SW620 cells, flow cytometry 
analysis of cells pulse labelled with EdU and counterstained with propidium iodine (PI) was 
performed on samples harvested after 7 hours and 24 hours (Figure 4.6: B). This showed a 
lower proportion of cells in S phase with Ros and CVT treatment after 7 hours. This effect was 
enhanced after 24 hours treatment, resulting in greatly reduced proportion of cells in S phase 
with PHA, Ros and CVT treatment (Figure 4.4).  Flow cytometry results show a substantial 
reduction in cell cycle progression with PHA, Ros and CVT. There is also a reduction in G2 
cells with XL treatment (Figure 4.4: B). PD  also shows a small reduction compared to control. 
Overall, the data show that the DDK inhibitor PHA767491 as well as the CDK2 inhibitors Ros 
and CVT efficiently reduce CIZ1 protein levels and arrest cells in G1 and G2 phases with a 
reduction in S phase cells. Importantly, there is a strong correlation between the efficacy of 
CIZ1 reduction and the proliferative potential of the cells. 
 
 





Figure 4.4: Treating SW620 cells with CDKis and DDKis. Cells were treated with PD, PHA, 
XL, Ros and CVT. A. Cells were treated with drugs for 7 and 24 hours. Western blots were 
probed with CIZ1, pCIZ1-T293, MCM2, pMCM2-S53 and Actin. B. Multiparameter flow 
cytometry dot plot showing EdU intensity (y-axis) vs total DNA (x-axis) assessing the effect of 
each drug on cell cycle profile and entry to S-phase. Data shows n=1. 




4.3.2 Neural cells 
Having established a proof of principle in being able to show that CDK and DDK inhibition 
reduces CIZ1 levels in other cancer types, this approach was evaluated in BTNW914 primary 
glioblastoma, U87MG and transformed glia SVGp12 cells. CIZ1 protein levels were evaluated 
after inhibitor treatment, as was the rate of proliferation. Proliferation was measured in relation 
to CIZ1 expression as it has an important role in the control and promotion of DNA replication, 
and interacts with cyclins, coordinating their function (Copeland et al., 2010). CIZ1 is also a 
CDK sensor that promotes initiation of DNA replication and prevention of re-replication 
(Copeland et al., 2015). Measuring rate of proliferation shows that CDKis and DDKis may be 
reducing CIZ1, which in turn should reduce proliferation. However, it is important to keep in 
mind that inhibiting CDKs would likely in themselves reduce proliferation as they are key 
components of the cell cycle.  
 
Cells were treated with CDK4/6 (PD), DDKis (PHA and XL), and CDK2 inhibitors (Ros and 
CVT). Cells were harvested at 7 hours or 24 hours and probed for CIZ1, pCIZ1 and MCM2.  
Western blots from BTNW914 cells (figure 4.5: A) revealed CIZ1 levels are reduced at 24 
hours when treated with PHA and Ros. Interestingly, a reduction in CIZ1 with PD at 24 hours 
is now seen. It is worth noting that a fresh batch of PD was used, which appeared to be more 
potent compared to the original batch. This may explain the sudden decrease seen in CIZ1 
levels that have not been seen up to this point. In contrast with earlier results, CVT did not 
reduce CIZ1 or levels of pT293 which may be the result of a failure of response in this cell line. 
To determine the effects of the drugs on proliferation, a PrestoBlue assay was performed. This 
showed that the control, PD and XL samples showed an increase in proliferation, whereas 
there was a reduction in proliferation with PHA, Ros and CVT treatment (Figure 4.5B). The 
results show that there is a correlation between CIZ1 levels that correlates with 
phosphorylation of CIZ1. However, when measuring proliferation, there is a correlation 
between CDK2 inhibition and proliferation as Ros, CVT and PHA are all CDK2 inhibitors with 




IC50 <0.6 µM. Taken together, this shows that reducing CIZ1 levels by inhibiting CDK2 may 
reduce cell proliferation.  
 
 
Figure 4.5: Treating BTNW914 cells with CDKis and DDKis. Cells were treated with PD, 
PHA, XL, Ros and CVT. A. Cells were treated with drugs for 7 and 24 hours. Western blots 
were probed with CIZ1, pCIZ1-T293, MCM2 and Actin. B. PrestoBlue assay was performed 
after 0, 24, 48 and 72 hours. Data shows the mean and standard deviation for 3 technical 
replicates where n=1. 
 
The analysis was extended using the glioblastoma cell line U87MG. As with the BTNW914 
cells, the U87MG cells were treated with a CDK4/6 inhibitor (PD), DDKis (PHA and XL), and 
CDK2 inhibitors (Ros and CVT) then harvested at 7 hours and 24 hours and probed for CIZ1, 




pCIZ1, MCM2 and pS53. In contrast to the BTNW914 cells, the addition CDK or DDK inhibitors 
appears to have a minimal impact on CIZ1 levels at both 7 hours and 24 hours. A slight 
decrease is seen with CVT, and a smaller decrease with Ros. This may be because this cell 
line is less sensitive to these drugs due to an unknown mechanism, or perhaps 24 hours is 
not be enough time for CIZ1 degradation. Reduction in T293 phosphorylation is seen with 
PHA, Ros and CVT treatment, similar to what we have seen in all BTNW914 and SW620 cells. 
Strangely, at 24 hours, there also seems to be an increase in both CIZ1 and CIZ1 
phosphorylation with XL, although this may be due in part to a slightly uneven sample load 
compared to control. Overall, there is a less reduction in CIZ1 expression in U87MG cell lines 
between the control and DDK kinase inhibitor treatments, but there is a reduction when using 
CDK2 inhibitors Ros and CVT. The PrestoBlue proliferation assay shows a moderate 
reduction in proliferation with PHA, XL, Ros and CVT relative to control (Figure 4.6B). The 
inhibition of CDK4/6 does not appear to affect proliferation with proliferation rates similar to 
control at 48 and 72 hours. However, in contrast to the Western blot, proliferation is reduced 










Figure 4.6: Treating U87MG cells with CDKis and DDKis. Cells were treated with PD, PHA, 
XL, Ros and CVT. A. Cells were treated with drugs for 7 and 24 hours. Western blots were 
probed with CIZ1, pCIZ1-T293, MCM2 and Actin. B. PrestoBlue assay was performed after 0, 
24, 48 and 72 hours. Data shows the mean and standard deviation for 3 technical replicates 
where n=1. 
 
After comparing the effects of the drugs on glioblastoma cell lines, cell line SVGp12 cells were 
used as a ‘normal’ control. Western blot results show PHA, Ros and CVT treatment reduced 
CIZ1 protein levels, and there is also a reduction for CIZ1 levels after XL treatment that 
contrasts with glioblastoma primary cells and cell lines. Consistent with reduction in CIZ1 
levels correlating with reduced proliferation, PHA, Ros and CVT all reduced proliferation, and 




XL also showed a moderate reduction in proliferation, mirroring the loss of CIZ1 from the 
Western blot. Proliferation with PD jumps up above the control rate of proliferation, in a similar 





Figure 4.7: Treating SVGp12 cells with CDKis and DDKis. Cells were treated with PD, 
PHA, XL, Ros and CVT. A. Cells were treated with drugs for 7 and 24 hours. Western blots 
were probed with CIZ1, pCIZ1-T293, MCM2 and Actin. B. PrestoBlue assay was performed 
after 0, 24, 48 and 72 hours Data shows the mean and standard deviation for 3 technical 








4.4 Chapter Discussion 
4.4.1 Knockdown of CIZ1 reduces proliferation and cell cycle progression 
CIZ1 contributes to tumorigenesis in a number of tumours including breast (den Hollander et 
al., 2006), colorectal (Wang et al., 2014, Yin et al., 2013), hepatocellular carcinoma (Wu et al., 
2016), gall bladder (Zhang et al., 2015), prostate (Liu et al., 2015), small cell lung and non-
small cell lung carcinoma (Higgins et al., 2012). In each case, CIZ1 has been implicated 
directly in tumour growth due to overexpression or alternative splicing (Higgins et al., 2012, 
Swarts et al., 2018). 
  
Using siRNA to reduce CIZ1 levels is an approach that has been used both in vitro and in vivo, 
successfully causing a corresponding reduction in tumour growth in mouse models (Higgins 
et al., 2012, Liu et al., 2015, Wu et al., 2016) and cellular proliferation in colorectal cancer (Yin 
et al., 2013) and prostate cancer (Pauzaite, 2019) cell lines. The efficacy of this approach in 
previous studies lead to the justification and reasoning for using this approach on glioblastoma 
cells. Consistent with earlier reports, depletion of CIZ1 reduced proliferation in BTNW914 
primary glioblastoma cells as reported by reduction in KI67 and proliferation assays. However, 
this information comes from only one data set, therefore more repeats would be needed to 
validate this. Additionally, in future work, at least 2 independent CIZ1 siRNAs should be used 
in order to confirm phenotypes observed are not off-target effects a particular siRNA. 
Nonetheless, as there are currently no effective treatments for glioblastoma, demonstrating 
that a reduction in CIZ1 is able to reduce proliferation is a promising start, especially as these 
results follow the same patterns as previous works. These results suggest that approaches 
that reduce CIZ1 levels may be beneficial for the treatment of glioblastoma. 
 




4.4.2 CDK and DDK inhibitors reduce CIZ1 and proliferation 
CDKis and DDKis have been previously shown to reduce CIZ1 levels and proliferation. 
(Pauzaite, 2019). The use of CDK inhibitors is based on the proposed model, which predicts 
that CIZ1 levels are controlled by CDKs and UPS (Figure 4.1) (Pauzaite, 2019). This model 
predicts that CDK activity is required for accumulation of CIZ1 and prevents UPS mediated 
degradation. Therefore, it predicts that inhibition of CDK activity may reduce CIZ1 levels.  
In this work, we were able to establish that there is a correlation between reduction of CIZ1 by 
CDK and DDK inhibitors and proliferation. In particular, PHA, Ros and CVT resulted in 
decrease CIZ1, with a decrease in proliferation seen in all three cell types used, including the 
normal SVGp12 cell line. In contrast, the DDK inhibitor XL413, produced inconsistent results 
and occasionally saw increased CIZ1 levels but also saw a decrease in proliferation with 
U87MG. This decrease is not seen in BTNW914 or SVGp12. This may be related to the 
bioavailability of the inhibitor as earlier studies have shown that XL413 is effective in only a 
limited number of cancer cell lines that is associated with its solubility (Sasi et al., 2014). Again, 
it is worth mentioning that inhibiting CDKs and DDKs would likely in themselves reduce 
proliferation as key components of the cell cycle, therefore need to be aware that any reduction 
in proliferation may be the direct result of these inhibitors. Future work looking at the UPS part 
of the proposed CIZ1 regulation model (Figure 4.1) may help determine to what extent 
proliferation is affected by CIZ1 levels.  
 
There are currently no approved CDK2 inhibitors, preventing the use of CDK2 inhibition in 
glioblastoma in clinical studies. However, PD is approved for clinical use. Its current use is in 
the treatment of in breast cancer in post-menopausal women that is oestrogen receptor 
positive and HER2 negative (De Luca et al., 2018). There was one instance where the effects 
on proliferation and cell cycle progression seen with PD were similar to that seen with  PHA, 
Ros and CVT (Figure 4.5). In this instance, a new batch of PD was made up and used. This 
new batch was made up to a concentration that would be considered clinically relevant. 




Multiple repeats and experiments would be necessary to test and validate this, but this 
provides evidence for the use of CDK inhibitors as potential strategy for the treatment of 
glioblastoma. 
 
The experiments conducted throughout provides evidence that supports the model that 
predicts that CIZ1 is regulated by opposing CDK and UPS activity (Figure 4.1). This model 
suggests avenues to specifically reduce CIZ1 levels through modulation of UPS activity. This 
work extends the observations of its potential in colorectal, prostate and breast cancers 
(Pauzaite, 2019). However, it would make a more complete picture of the model to be able to 
conduct experiments which showed that blocking the UPS system would result in an increase 
in CIZ1 due to the inability to degrade it. The identification of the E3 ligases are involved would 
be of great benefit as there is potential that this knowledge could be used to identify patients 
that may benefit from this strategy. This information would allow us to have a better 
understanding of how CDKis and DDKis work in reducing CIZ1 levels. 
 
Additional work is required to expand the analysis of the use of CDK inhibitors. Although only 
one repeat was successfully carried out, it showed great promise in reducing proliferation in 
tumour cells. Repeating this will hopefully provide the evidence needed. Use of CDK inhibitors 
as a potential cancer treatment is expanding. Palbociclib is a CDK4/6 inhibitor which is 
currently approved for use in certain breast cancers. Dinaciclib is another potent CDK inhibitor 
which was granted orphan drug FDA status in 2011, and is currently in clinical trials for 
numerous cancer types, including stage III clinical trials for chronic lymphoblastic leukaemia 
(Ghia et al., 2017). Dinaciclib also shows promise for myeloma treatment (Kumar et al., 2015). 
Additionally, expanding upon the proliferation assay to include more assays such as migration, 
invasion and cell death would give greater insight into how effective using CDK and DDK 
inhibitors as a potential treatment may be. In vivo work to support evidence found so far may 




be considered if the trend continues. Taken together, this work shows that CIZ1 is a potential 
target in glioblastoma, and there is future potential for using CDKis as treatment.  
  



























Chapter 5: General Discussion 
  




5.1 Implications of the work 
This work has evaluated the potential for CIZ1 as a diagnostic biomarker for glioblastoma. A 
strong and clear distinction was seen in CIZ1 staining between tumour and non-tumour 
sections in 3 of the 6 FFPE sections. In the other 3 sections, CIZ1 staining was still apparent, 
but less clear and striking. Nonetheless, CIZ1 was able to identify tumour areas specifically in 
all 6 patients. CIZ1 also identified and enhanced visualisation of micrometastases and clonal 
variation within a tumour area. Taken together, this work gives a strong case for potential 
future use of CIZ1 as a diagnostic biomarker. This could be beneficial as there is a lack of a 
unifying biomarker specific to glioblastoma. As a highly heterogenetic cancer, having this 
biomarker could help accelerate the diagnostic process. 
 
5.2 Limitations and future work 
This work has made headway into the use of CIZ1 as a biomarker. The major limitation to this 
section of the work is that only 6 FFPE tumours were used for IHC analysis. In future works, 
using a significantly increased number of patient samples to perform IHC would allow us to 
determine the efficacy and sensitivity of the assay, and have a much better understanding of 
the potential role CIZ1 has in glioblastoma. From the samples used, we were able to conclude 
that there does appear to be a relationship between CIZ1 expression and tumour occurrence.  
 
There is a strong case for CIZ1 as a biomarker, but this is currently limited to diagnosis. It may 
be feasible to relate CIZ1 staining to patient outcome. The work presented here demonstrates 
that CIZ1 is expressed at high levels and aberrantly localised. However, the prognostic 
potential of CIZ1 remains to be addressed. There is a need to use longitudinal data to 
determine the consequences of high CIZ1 levels. Here, 6 patient samples were used. In future 
experiments, more samples would give us more information and more data to draw stronger 
conclusions from. Due to lack of longitudinal data, age and sex to accompany each patient 




sample used, we were unable to draw any conclusions as to whether CIZ1 expression has an 
impact on prognosis. Going forward, collecting this data would be useful. Additionally, extra 
controls could be performed to test the specificity of the antibody staining such as a blocking 
peptide control for IHC work and siRNA controls for immunofluorescence work in cell lines. 
 
It would also be of interest to see whether there a link between the tumour subtype (classical, 
mesenchymal, neural, proneural) and CIZ1 levels, and whether CIZ1 labels them differently. 
Having access to data such as which biomarkers were used for diagnosis and tested positively 
and negatively would be useful in determining which subtype each patient came under, and 
whether there is a correlation between CIZ1 and a particular subtype. As some patients 
respond better to certain treatments according to which glioblastoma subtype they have, CIZ1 
may also be used as both a diagnostic and prognostic biomarker and may help direct 
personalised treatment. 
 
The mislocalisation of CIZ1 is yet to be understood. There are a number of possible 
explanations for the aberrant expression of CIZ1 seen in glioblastoma. One possible reason 
is glioblastoma cells suffer a loss of nuclear localisation signal (NLS) due to splicing. It is 
unknown how changes in localisation affect its function as most described functions are 
nuclear. Loss affects nuclear function is a possibility in this scenario. Additionally, we have 
found that not only glioblastoma cells show mislocalisation. Normal glial cells also have 
cytosolic distribution in addition to nuclear according to our fractionation and 
immunofluorescence data. Neurons also display cytosolic localisation as seen in our IHC data. 
Endothelial cells also show CIZ1 stain, but from our data, it appeared only to show stain when 
within a tumour area. In future work this would be worth exploring as this might have an 
implication in disease pathogenesis.  
 




The work on the modulation of CIZ1 shows efficacy of CDKi/DDKi leading to CIZ1 reduction, 
alongside the proliferation assays has provided evidence for use of CDKis and DDKis in 
reducing proliferation of glioblastoma tumour cells. The basis for starting this work relied on 
the siRNA work in reducing CIZ1 and previous work where CDKis/DDKis were used effectively 
(Pauzaite, 2019). The siRNA work is only comprised of a single repeat, which requires further 
experimental validation. Additionally, expanding upon the proliferation assay to include more 
assays such as migration, invasion and cell death would give greater insight into how effective 
using CDK and DDK inhibitors as a potential treatment may be. In vivo work to support 
evidence found so far may be considered if the trend continues. The CIZ1 regulatory model  
(Figure 4.1) whereby CIZ1 is regulated by the opposing CDK/UPS system, suggests that use 
of CDK inhibitors as a potential glioblastoma treatment and necessitates additional work to 
fully understand how CIZ1 is regulated. The work concludes that CIZ1 may be a potential drug 
target in glioblastoma and additional work is required to validate its efficacy in vitro and in vivo. 
 
5.3 Concluding remarks  
To conclude, this work has found that CIZ1 is specific to glioblastoma tumour cells, making it 
a potentially viable biomarker. More samples and accompanying patient data will reveal its 
potential as an effective diagnostic and prognostic biomarker. 
 
We have found an unusual localisation pattern in these cells. Whereas CIZ1 is normally 
located in the nucleus, this work has found using multiple ways that CIZ1 is found in both the 
nucleus and cytoplasm. As of yet, the mechanism of CIZ1 mislocalisation remains to be 
determined. However, the mislocalisation provides aids in the visualisation of CIZ1 stained 
tumour cells and may enhance the ability of CIZ1 to be used as a biomarker in glioblastoma. 
 
We have confirmed that reduction of CIZ1 correlates with a reduction in proliferation. 
Additionally, the use of some CDKis and DDKis that have been used to reduce CIZ1 levels 




previously in different cell types, also are able to do so in glioblastoma cells, in turn also 
resulting in reduced proliferation. These results suggest that modulation of CIZ1 levels is 
feasible pharmacologically and this represents a potential strategy to reduce CIZ1 levels in 
tumours. This approach requires new molecules that can specifically inhibit CDK2 activity that 
are able to show efficacy in clinical trials. At this stage, the results show promise and require 
extension of this work. This work demonstrates that CIZ1 may contribute to glioblastoma 
growth and that the use of CDKis and DDKis are able to reduce CIZ1 levels and proliferation. 
Consequently, there is the potential for the repurposing of similar kinase inhibitors for future 
therapeutic use in glioblastoma.   
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